Reportable Segment — Marketing, selling, and administrative
Business Segments · Marketing, selling, and administrativeEli Lilly Reportable Segment — Marketing, selling, and administrative increased by 14.3% to $3.13B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 29.2%, from $2.42B to $3.13B. Over 3 years (FY 2022 to FY 2025), Reportable Segment — Marketing, selling, and administrative shows an upward trend with a 19.9% CAGR.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ4 2025
Rolls up toSG&A
How to read this metric
An increase relative to revenue may signal aggressive investment in new product launches, while a decrease could indicate cost-optimization efforts or reduced commercial activity.
Detailed definition
Captures the operating expenses related to the promotion, distribution, and general management of the segment's business...
Peer comparison
Comparable to SG&A expenses allocated to specific business units in peer pharmaceutical companies.
Metric ID:
lly_segment_reportable_segment_marketing_selling_and_administrativeHistorical Data
16 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.61B | $1.61B | $1.61B | $1.61B | $1.85B | $1.85B | $1.85B | $1.85B | $1.95B | $2.12B | $2.10B | $2.42B | $2.47B | $2.75B | $2.74B | $3.13B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +14.9% | +0.0% | +0.0% | +0.0% | +5.5% | +8.5% | -0.8% | +15.5% | +1.8% | +11.5% | -0.4% | +14.3% |
| YoY Change | — | — | — | — | +14.9% | +14.9% | +14.9% | +14.9% | +5.5% | +14.4% | +13.5% | +31.0% | +26.5% | +30.0% | +30.5% | +29.2% |
Range$1.61B – $3.13B
CAGR+19.4%
Avg YoY Growth+20.0%
Median YoY Growth+14.9%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — marketing, selling, and administrative?
- Eli Lilly (LLY) reported reportable segment — marketing, selling, and administrative of $3.13B in Q4 2025.
- How has Eli Lilly's reportable segment — marketing, selling, and administrative changed year-over-year?
- Eli Lilly's reportable segment — marketing, selling, and administrative increased by 29.2% year-over-year, from $2.42B to $3.13B.
- What is the long-term trend for Eli Lilly's reportable segment — marketing, selling, and administrative?
- Over 3 years (2022 to 2025), Eli Lilly's reportable segment — marketing, selling, and administrative has grown at a 19.9% compound annual growth rate (CAGR), from $6.44B to $11.09B.
- What does reportable segment — marketing, selling, and administrative mean?
- Operating expenses spent on selling, marketing, and managing the segment's business.